Next, we exploited our analysis of individual phosphoproteomic data of T and NAT using KSEA to identify kinases that were activated in pre-treatment HER2-positive and HER2-negative gastric cancer (Fig. 7a,b, Table S9, S10). This evidence concerns the gene BRD2 and gastric cancer.